Amphastar Pharmaceuticals, Inc.

AMPH

US03209R1032

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 18/06/2024 am IST			5-day change	1st Jan Change
40.54 ^USD	+0.12%		-2.64%	-34.45%

04/06	Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director	CI
04/06	Amphastar Pharmaceuticals' Board Approves $50 Million Increase to Share Buyback Plan	MT

Tranche Update on Amphastar Pharmaceuticals, Inc.'s Equity Buyback Plan announced on November 8, 2016.

February 01, 2024 at 02:43 am IST

From October 1, 2023 to December 31, 2023, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 10,078,173 shares, representing 21.3% for $228.89 million under the buyback announced on November 8, 2016.

Latest news about Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director	05/06	CI
Amphastar Pharmaceuticals' Board Approves $50 Million Increase to Share Buyback Plan	04/06	MT
Amphastar Pharmaceuticals, Inc. announces an Increase in Equity Buyback.	03/06	CI
Sector Update: Health Care Stocks Slightly Higher Late Afternoon	23/05	MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon	22/05	MT
Amphastar Pharmaceuticals Gains US FDA Approval for Generic Bronchospasm Drug	22/05	MT
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol	22/05	CI
Transcript : Amphastar Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM	16/05
Tranche Update on Amphastar Pharmaceuticals, Inc.'s Equity Buyback Plan announced on November 8, 2016.	10/05	CI
Transcript : Amphastar Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024	09/05
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 EPS $1.04, vs. Street Est of $0.79	09/05	MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 Revenue $171.8M, vs. Street Est of $174.7M	09/05	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	01/05	MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	30/04	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04	MT
Transcript : Amphastar Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM	13/03
Amphastar Pharmaceuticals Insider Sold Shares Worth $842,883, According to a Recent SEC Filing	09/03	MT
JPMorgan Initiates Amphastar Pharmaceuticals With Overweight Rating, Price Target is $60	05/03	MT
Tranche Update on Amphastar Pharmaceuticals, Inc.'s Equity Buyback Plan announced on November 8, 2016.	01/03	CI
Sector Update: Health Care Stocks Advance Premarket Thursday	29/02	MT
Amphastar Pharmaceuticals Q4 Adjusted Earnings, Revenue Rise	29/02	MT
Transcript : Amphastar Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024	29/02

Chart Amphastar Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.

Sector

Pharmaceuticals

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Amphastar Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

40.54 USD

Average target price

62.6 USD

Spread / Average Target

+54.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AMPHASTAR PHARMACEUTICALS, INC.	-34.45%	1.98B
ELI LILLY AND COMPANY	+51.82%	797B
NOVO NORDISK A/S	+40.70%	628B
JOHNSON & JOHNSON	-6.88%	351B
MERCK & CO., INC.	+16.95%	323B
ABBVIE INC.	+9.49%	300B
ASTRAZENECA PLC	+17.02%	244B
ROCHE HOLDING AG	+0.90%	223B
AMGEN INC.	+5.30%	163B
PFIZER, INC.	-6.29%	153B

Other Pharmaceuticals

Amphastar Pharmaceuticals, Inc.

Equities

AMPH

US03209R1032

Pharmaceuticals

Tranche Update on Amphastar Pharmaceuticals, Inc.'s Equity Buyback Plan announced on November 8, 2016.

EPS Revisions